Result card

  • CUR1: Which disease/health problem/potential health problem will Genetic Test be used for?
English

Which disease/health problem/potential health problem will Genetic Test be used for?

Authors: Sarah Baggaley, Massimo Gion

Internal reviewers: Luciana Ballini, Aurora Llanos, Antonio Migliore, Claudia Wild

The information used for this section was from other HTAs, evidence-based guidelines and the manufacturers’ websites.

Treatment of primary breast cancer usually involves surgery to remove the breast tumour and any involved lymph nodes, followed by adjuvant therapy to reduce the risk of breast cancer recurrence. Recurrence can occur when some cancer cells remain after surgery or when previously unidentified cancer cells have spread to areas around the breast or other areas of the body {1}.

Breast cancer does not recur in all cases and therefore, some patients may experience harmful side-effects of adjuvant therapy unnecessarily {2}. The uPA/PAI-1, MammaPrint and Oncotype DX tests are intended to predict the likelihood of breast cancer recurrence in women and to support the tailoring of treatment to the individual patient.

Specifically,

  • The uPA/PAI-1 test is intended for women with newly diagnosed lymph node-negative breast cancer {3}.
  • MammaPrint is intended for women {4}:
    • with lymph node-negative and lymph node-positive breast cancer with a tumour size of 5 cm or less or for women
    • who are 61 years of age or less, with oestrogen receptor- positive or oestrogen receptor-negative, lymph node-negative breast cancer.
  • The Oncotype DX assay is intended for women with newly diagnosed lymph node-negative or lymph node-positive, oestrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer {5}.
Critical
Completely
Baggaley S, Gion M Result Card CUR1 In: Baggaley S, Gion M Health Problem and Current Use of the Technology In: Jefferson T, Vicari N, Raatz H [eds.]. Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX ) [Core HTA], Agenzia nationale per i servizi sanitari regionali (age.na.s), Italy ; 2013. [cited 3 December 2022]. Available from: http://corehta.info/ViewCover.aspx?id=113

References